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BMP4(FGFs) are required for brain, pharyngeal arch, suture and neural crest cell
development and mutations in the FGF receptors have been linked to human craniofacial malformations. To
study the functions of FGF during facial morphogenesis we locally perturb FGF signalling in the avian facial
prominences with FGFR antagonists, foil barriers and FGF2 protein. We tested 4 positions with antagonist-
soaked beads but only one of these induced a facial defect. Embryos treated in the lateral frontonasal mass,
adjacent to the nasal slit developed cleft beaks. The main mechanisms were a block in proliferation and an
increase in apoptosis in those areas that were most dependent on FGF signaling. We inserted foil barriers
with the goal of blocking diffusion of FGF ligands out of the lateral edge of the frontonasal mass. The barriers
induced an upregulation of the FGF target gene, SPRY2 compared to the control side. Moreover, these changes
in expression were associated with deletions of the lateral edge of the premaxillary bone. To determine
whether we could replicate the effects of the foil by increasing FGF levels, beads soaked in FGF2 were placed
into the lateral edge of the frontonasal mass. There was a signiﬁcant increase in proliferation and an
expansion of the frontonasal mass but the skeletal defects were minor and not the same as those produced
by the foil. Instead it is more likely that the foil repressed FGF signaling perhaps mediated by the increase in
SPRY2 expression. In summary, we have found that the nasal slit is a source of FGF signals and the function of
FGF is to stimulate proliferation in the cranial frontonasal mass. The FGF independent regions correlate with
those previously determined to be dependent on BMP signaling. We propose a new model whereby, FGF-
dependent microenvironments exist in the cranial frontonasal mass and caudal maxillary prominence and
these ﬂank BMP-dependent regions. Coordination of the proliferation in these regions leads ultimately to
normal facial morphogenesis.
© 2008 Elsevier Inc. All rights reserved.IntroductionDuring ontogeny of the face, several initially separate buds of
mesenchyme covered in epithelium known as the facial prominences
grow out and merge together to give rise to the upper and lower jaws.
The majority of the mesenchyme within the facial prominences is
derived from cranial neural crest cells, with a smaller contribution
from paraxial head mesoderm. The neural crest derived mesenchyme
gives rise to all of the bone and cartilage in the face (Couly et al., 1996;
Couly et al., 1993; Kontges and Lumsden, 1996; Noden, 1983). The
majority of skeletal patterning information is carried in the neural
crest-derived mesenchyme (Schneider and Helms, 2003; Tucker and
Lumsden, 2004). Soon after neural crest cell migration ends, the facial
prominences form around the primitive oral cavity. The frontonasal
mass lies in the midline and is ﬂanked by the nasal pits, the lateral
nasal prominences are between the nasal pit and the eye, the
maxillary prominence are at either side of the oral cavity, whereaschman).
t of Craniofacial Development,
l rights reserved.the mandibular prominences lie below the maxillary prominences.
The upper jaw is formed by the frontonasal mass with contributions
from the maxillary and lateral nasal prominences. In contrast, the
lower jaw is formed entirely by the mandibular prominences. To form
the upper beak there must be contact between the corners (globular
processes) of the frontonasal mass and maxillary prominences.
Following growth and contact of the two prominences, a bilayered
epithelial seam is formed and then is removed through apoptosis and
epithelial–mesenchymal transformation (Sun et al., 2000). The
degrading epithelium is invaded by mesenchyme from either side
and residual grooves are ﬁlling out by proliferation.
Even though the bigger aspects of jaw identity are established
prior to the formation of facial prominences (for example, distinguish-
ing upper versus lower jaws), reﬁnement of the basic pattern is still
required to give species-speciﬁc morphology. Work carried out in
avian embryos has shown that expression of certain growth factors
such as Bone Morphogenetic Proteins (BMPs) is correlated with
differences in beak shape (Abzhanov et al., 2004; Wu et al., 2004). For
example, the shape of the early frontonasal mass is thought to be
closely related to the ﬁnal shape of the upper beak. Themechanism for
modifying frontonasal mass morphology is thought to be by the
positive inﬂuences of growth factors on proliferating cells within the
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the demonstration in several studies that antagonism of BMP
signaling with Noggin reduces the proliferation and consequently
the size of facial prominences (Ashique et al., 2002a; Foppiano et al.,
2007; Wu et al., 2006, 2004).
In addition to BMPs, several other growth factor families are known
to be important for growth of facial prominences. Wingless-related
proteins (Wnt) constitute one class of signal required for frontonasal
mass growth. In experimentswhere embryoswere exposed toDkk1, an
antagonist of Wnt signaling, frontonasal mass growth was inhibited
and clefts occurred (Brugmann et al., 2007). The epithelially-expressed
gene Sonic Hedgehog is required at two times in development, early on
to establish the facial midline and later to promote outgrowth of the
frontonasal mass (Hu and Helms, 1999; Hu et al., 2003). BMPs are
required to establish the SHH expression domain in the caudal edge of
the frontonasal mass (Foppiano et al., 2007).
The contribution of FGF signaling to midfacial growth and the
fusion of the upper lip has been addressed in several conditional
deletions of Fgf8. In several lines, the mutant embryos have a
truncated face (Macatee et al., 2003) and mandible (Trumpp et al.,
1999), suggesting that FGF signaling may be required at speciﬁc times
in development. In addition, there are intriguing data suggesting that
prolonged expression of FGF8 and maintenance of proliferation at
higher levels at the edges of the frontonasal mass is one of the reasons
why the duck has a wider beak than the chicken (Wu et al., 2006).
However no one has rigorously studied the role of FGFs in facial
morphogenesis.
There are 22 FGF ligands in mammals (Zhang et al., 2006), ﬁve of
which are expressed in the mouse face Fgf2, Fgf8, Fgf9, Fgf10, Fgf17 and
Fgf18 (Bachler and Neubuser, 2001; Crossley and Martin, 1995; Havens
et al., 2006; Karabagli et al., 2002; Kettunen and Thesleff, 1998; Rice et
al., 2004). In the chicken genome only 5 of these genes are present,
including FGF2, FGF8, FGF9, FGF10 and FGF18. Of these genes, FGF2 is
ubiquitously expressed, and the others are mainly expressed in the
superﬁcial ectoderm surrounding the nasal slit and lining the maxillo-
mandibular cleft (Havens et al., 2006; Karabagli et al., 2002;
McGonnell et al., 1998; Ohuchi et al., 2000; Richman et al., 1997).
FGFs bind to three FGF receptors in the facial mesenchyme. FGFR1 is
expressed ubiquitously whereas FGFR2, is expressed in the medial
frontonasal mass mesenchyme while FGFR3 is restricted to the caudal
edge of the frontonasal mass and medial edges of the maxillary
prominences (Matovinovic and Richman, 1997; Wilke et al., 1997).
Our study focuses on the control of facial morphogenesis using
gain or loss of function approaches that target the FGF pathway. Since
there are so many FGF family members, to decrease signaling, we
implanted beads soaked in a pan-antagonist of FGFRs, SU5402
(Mohammadi et al., 1997). To increase FGF receptor activation FGF2
protein was applied to discrete regions of the face. Our results
revealed several novel FGF-dependent and independent regions in the
frontonasal mass and maxillary prominence that together coordinate
growth and contact of the facial prominences. Finally, to determine
where the FGF signal originated, we implanted foil barriers to block
directional signaling in the frontonasal mass.
Methods
Bead implantations and foil implants
White leghorn eggs were obtained from the University of Alberta and incubated at
38 °C. SU5402 (SUGEN, USA and EMD Biosciences, UK; Mohammadi et al., 1997) was
dissolved in DMSO (dimethyl sulfoxide). AG1X2 beads (Formate form, Biorad) were
soaked in 5 μl of SU5402 for 1 h with a drop of 0.01% Fast Green added for bead
visualization. FGF2 beads were prepared by soaking 200–300 μm Afﬁgel beads with
either 1 mg/ml FGF2 or FGF8b protein (Peprotech). Control beads were soaked in DMSO
or buffer. Beads were inserted into small incisions into the facial prominences and the
ﬁnal position was recorded.
Aluminium foil was inserted medial to the nasal slit in the frontonasal mass. Care
was taken to position the foil cranially and not to interfere with the globular process.Skeletal preparation and skull analysis
To study bone and cartilage morphology Hamburger and Hamilton stage 37–39
(E12–14) embryos were stained as described (Plant et al., 2000). Each process of the
maxilla, premaxilla and palatine bones was compared to the normal, contralateral side.
Bony processes were scored as normal, reduced or absent. The reduced category
included bony processes that were greater than 50% shorter in length. The effect of
SU5402 bead position on skeletal morphology was determined using χ2 analysis
(signiﬁcance level set at pb0.05).
Fluorescence photography of whole heads and analysis of early phenotypes with FGF2
beads
Embryos were ﬁxed in 4% paraformaldehyde (PFA) in phosphate buffered saline
(PBS) overnight, stained in 1:5000 dilution of SybrSafe (Invitrogen) in PBS for 10 min,
rinsed and photographed using the GFP ﬁlter on a Leica MZFLIII microscope.
BrdU analysis
Approximately 50 μl of 102 M BrdU (bromodeoxyuridine) was injected into the
heart 2 h prior to collection. Embryos were ﬁxed 12 h after bead implantation. Wax
sections (7 μm) were treated with proteinase K, exonucleases and then incubated with
neat primary antibody (Amersham, GE Healthcare). Alexa Fluor 488 (Molecular Probes,
Invitrogen) labeled goat anti-mouse antibody (1:50) was incubated at room
temperature for 30 min. Slides were coverslipped using Prolong Gold Antifade with
DAPI (Molecular Probes, Invitrogen).
Proliferation index was calculated by dividing the number of BrdU positive cells by
the DAPI positive (total cell number). Sections at least 14 μm apart were chosen so that
different populations of cells would be represented. We used twoWCIF Image J plugins
for automated cell counting: ITCN (Image-based Tool for Counting Nuclei) for the BrdU
positive cells and the Nucleus Counter for the DAPI stained nuclei.
To determine if there were differences in cell proliferation related to bead position
we divided the lateral frontonasal mass into thirds. The cranial region lined up with the
top edge of the nasal slit, the caudal region included the corner or globular process of
the frontonasal mass. Each area was approximately 200 μm wide by 100 μm tall and
contained approximately 800 cells. We compared each region counted, bead position
and compared SU5402 treatment to DMSO usingmultifactorial ANOVA (MANOVA) with
Fisher Least Signiﬁcant Difference post hoc testing (pb0.05; Statistica). In the FGF2-
treated embryos, changes in proliferation were qualitatively compared to the con-
tralateral side or Tris-treated controls.
Cell death analysis
For Nile Blue Sulfate staining, bead implantation was performed without neutral
red staining and embryos were collected 3, 6, and 9 h (Song et al., 2004). For TUNEL,
embryos were collected 6 and 16 h after bead implantation and sections were stained
as described (Buchtová et al., 2007). Apoptotic bodies in nearly adjacent sections were
counted in the same regions that were used in the BrdU analysis plus an additional
region in the medial frontonasal mass. Since apoptosis results in loss of cell integrity we
placed specimens into one of three categories: 0–5; 6–10; 11–50 apoptotic bodies
(Table S3).
Whole mount in situ hybridization and immunohistochemistry
Whole mount in situ hybridization was performed as described (Song et al., 2004).
Section in situ hybridization was performed with antisense 35S-labeled antisense
probes as described (Wilke et al., 1997). The following individuals generously provided
gallus cDNAs: G. Martin, SPRY2; P. Francis-West, BMP4; M. Kessel, DLX5; S. Wedden,
MSX1, MSX2; O. Pourquie, intronic and exonic FGF8; S. Keyse, PYST1. The SPRY4 probe
was obtained from the MRC Geneservice (UK; Clone ID: 603786019F1).
Embryos for wholemount phosphorylated MAPK staining were stained as
previously published (Corson et al., 2003) with the Phospho-p44/42 Map Kinase
antibody (Cell Signaling #9101; 1:350 dilution). An additional proteinase K step for
antigen retrieval was included.Results
Our study uncovered differential gene expression patterns within
the frontonasal mass and other regions of the face that led us to
hypothesize there were differences in FGF signaling within the
developing face. In order to understand the endogenous FGF signals
taking place at the time of fusionwe used bead implantation to locally
block or stimulate FGF signaling.We focused our study on stage 26–28
chicken embryos, a time when key differences in proliferation have
been noted (MacDonald et al., 2004; McGonnell et al., 1998; Wu et al.,
2006, 2004). These stages are also just prior to the major morpho-
genetic changes such as fusion of the lip and beak outgrowth. Our
Table 1
Effects of blocking FGF signaling vary according to bead position
a 6 are moderately reduced.
b 31 have ppmx dislocated proximally.
c 10 are severely truncated.
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degree of dependence on FGF signals in some areas of the face and not
in others. We also demonstrate through the use of barriers that it is
likely an FGF signal coming from the nasal pit that is required for
growth and skeletal patterning of the facial midline.
Loss of FGF signaling in the FNM induces a cleft phenotype — a notched
upper beak
We placed beads soaked in SU5402 into three positions in the
frontonasal mass and one in themaxillary prominence. Speciﬁcally we
targeted regions on either side of the fusion zone to determine
whether FGF signaling was required for lip fusion. Embryos were
treated at stage 26, approximately 16 h before epithelial contact in the
fusion zone takes place. There is also rapid proliferation within the
facial prominences at these stages, especially in the lateral edges of the
frontonasal mass (MacDonald et al., 2004; McGonnell et al., 1998; Wu
et al., 2006, 2004). We ﬁrst tested a variety of soaking concentrations
to determine the minimum concentration that would lead to
reproducible defects (Table S1). Based on these dose–response
experiments we selected 10 mg/ml as the optimal soaking concentra-
tion. Some embryos treated in the lateral edge of the frontonasal mass
with 10 mg/ml SU5402 developed cleft beak morphology (n=13/45)whereas those with beads placed in the midline of the frontonasal
mass (n=14/14, data not shown) or the anterior maxillary prominence
developed normally (n=15/15; Table 1). The placement of DMSO-
soaked beads did not affect morphogenesis (n=6/6).
In the next series of experiments we focused more on the lateral
edge of the frontonasal mass since this an area adjacent the FGF-rich
nasal slit epithelium. Beads were placed at opposite ends of the
frontonasal mass, cranial and in line with the superior edge of the
nasal slit or at the caudal edge, in the globular process. We found that
signiﬁcant numbers of embryos treated with cranial beads, developed
an external cleft (n=18/45; Table 1; Fig. 1A arrowhead). Skeletal
analysis revealed that several specimens with a normal external
appearance actually had defects in the bones supporting the edge of
the beak. In those embryos there was a gap between the premaxillary
andmaxillary bones (20/45; Table 1; Figs.1B–D) caused by a reduction
in size of the premaxillary bone (the maxillary process, nasal process
were reduced in 28/45 and 40/45 embryos respectively). Often, the
nasal conchae were unsupported and extended outside the nasal
capsule (n=25/45; Figs. 1B–D). The overall length of the upper beak
and growth of the midline prenasal cartilage was unaffected.
We were surprised to ﬁnd that all embryos treated in the globular
process had normal upper beaks (globular process, n=16/16, Figs.
1E–G; Table 1) even though there is expression of FGF8 in this region.
Fig. 1. Effects of SU5402 on beak morphology. External views (A, E) or stained skeletons (B, C, F–H) of stage 38 embryos originally treated at stage 26 or 20 with a bead soaked in
10mg/ml of SU5402. (A–D) Embryos treadwith cranial beads (inset in panel A) have notch in the tomium or cleft beak (CL). (B, C) Sagittal and palatal views of the beak. There is a cleft
between the maxillary and premaxillary bones, deviations of the upper beak towards the treated side however beak length is normal. In addition the maxillary bone is shifted
proximally and the nasal conchae extend beyond the conﬁnes of the nasal cavity. Panel D is a camera lucida drawing of the specimen in C illustrating the bonymorphology. (E–G) The
caudal bead position did not affect development. Beak morphology is normal externally (E) and internally (F, G). (H) Sagittal view of an embryo treated with bead placed in the
frontonasal mass at stage 20 (inset in panel E). The nasal bone is absent and nasal conchae are reduced on the treated side. Frontonasal mass derivatives are normal. The lower beak
has been removed. Scale bar=5 mm. Bar in D applies to B, F, C, G, H. Key: CL— cleft, mppmx —maxillary process of the premaxilla, mxb —maxillary bone, nb — nasal bone, nc, nasal
conchae, p — palatine bone, pmx — premaxillary bone, ppmxb — palatine process maxillary bone.
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FGF signaling was dispensable in the two areas of the face that must
meet for lip fusion to occur: the globular process andmedial maxillary
prominence.
The lack of effect on outgrowth of the upper beak by beads placed
into the centre or side of the frontonasal mass could indicate that
there are other times in development when there is a greater
dependence on FGF signaling for outgrowth of the upper beak. At
stage 20 there is strong expression of FGF8 across the superﬁcial
ectoderm of the entire frontonasal mass, and then it is downregulated
approximately 6 h later leaving only the transcripts surrounding the
nasal pit (Song et al., 2004). In order to determine whether stage 20
embryos were dependent on FGF signaling, we placed beads soaked in
SU5402 into the frontonasal mass. Instead of clefts or the predicted
beak truncations, the treatment with SU5402 led to slight deviations
of the prenasal cartilage and deletions of the nasal bone (Fig. 1H,
n=11/22). The effects on the nasal bone are in agreement with
previous studies where we have shown that FGFs are required for
lateral nasal prominence development at stage 20 (Song et al., 2004).The maxillary and palatine processes of the premaxillary bone were
also reduced in size (n=8/22). The lack of clefts at stage 20 versus stage
26 indicates the changing requirement for FGF signalling as the face
develops. We went on to focus on stage 26 embryo treated with
SU5402, since phenotypes were connected to an important aspect of
facial morphogenesis, fusion of the prominences. The data on
differential responsiveness to SU5402 in cranial and caudal bead
positions lead us to hypothesize that there were also differential gene
expression changes in FGF targets.
SU5402 blocks FGF signaling and decreases expression of FGF targets
within the frontonasal mass
In order to conﬁrm whether SU5402 had decreased endogenous
FGF signalingmore in the cranial frontonasal mass than the caudal, we
examined expression of three genes known to be directly regulated by
FGF ligands, SPRY2, SPRY4 and PYST1 (Chambers et al., 2000; Eblaghie
et al., 2003). SPRY2 is induced within 25 min of FGF application
(Chambers et al., 2000). Another family member, SPRY1 can be
Fig. 2. FGF signaling antagonists are differentially affected by cranial and caudal SU5402
bead positions. Wholemount in situ hybridization of embryos ﬁxed 16 h after beads
soaked in 10 mg/ml of SU5402 or DMSO were implanted. Position of beads is shown
with black arrowheads in all panels. (A, C, E, G, I) DMSO bead does not affect expression.
(B) SPRY4 and (D, F) SPRY2 expression are decreased in the lateral edge mesenchyme of
the frontonasal mass. Caudal beads (F) have a more local effect on expression than
cranial beads (D) where signal is reduced from the bead down to the globular process.
(H) Ablation of PYST1 expression with a cranial bead. (J) PYST1 expression is locally
decreased surrounding the caudal bead. Scale bar=500 μm. Key: fnm, frontonasal mass;
md, mandibular prominence; mxp, maxillary prominence.
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These studies suggest that the SPRY family members are direct targets
of FGF signaling. In addition to be induced by FGFs, SPRY proteins act
in a negative feedback loop to inhibit FGFR signaling by preventing the
downstream phosphorylation cascade (Kim and Bar-Sagi, 2004).During normal embryo development it is likely that SPRY proteins
maintain FGF homeostasis in areas where there are high levels of FGF
ligands. There is a close correlation between areas that express high
levels of FGF8 and those that express SPRY2 (Chambers and Mason,
2000). We also found the same relationship between SPRY2 and FGF8
in the face (Figs. 2C, E and data not shown). SPRY4 was expressed in
the almost the same areas as SPRY2 but frontonasal mass transcripts
for SPRY4were mainly concentrated at the cranial end of the nasal slit
(Fig. 2A).
We examined expression at 6 h to increase the probability of
identifying direct targets and at 16 h, to determine the duration of gene
expression changes. Beyond 16 h, many of the cranially treated spe-
cimens had deﬁciencies in the frontonasal mass, the ﬁrst indication
that a growth disturbance had occurred. Both SPRY4 and SPRY2
expressionwere reduced in embryoswith cranial beads 6 h after beads
were implanted (data not shown; Table S2). Sixteen hours after cranial
bead implantation, expression of SPRY4 had partially recovered near
the cranial edge of the nasal slit (Fig. 2B; Table S2). Less recovery of
SPRY2 was seen within the globular process itself where expression
continued to be weaker compared to the non-treated side (n=7/7; Fig.
2D). Themore robust recovery in some parts of the face could be due to
higher endogenous FGF levels in the regions near the nasal slit. Indeed
we found that SU5402 treatment did not decrease FGF8 transcripts
(Table S2) so once the antagonist had cleared from the tissue, we
assume that the translated protein could resume normal function.
In contrast, caudal beads decreased SPRY2 but the effects were
conﬁned mainly to the globular process at both 6 and 16 h after
implantation (6 h, n=7/7; 16 h, n=6/6; Fig. 2F, Table S2). The caudal
beads lay outside the expression domain of SPRY4, and therefore there
was no effect on expression (6 h, n=4/4; 16 h, n=10/10; data not
shown). We did not examine SPRY1 in our studies, because it has
nearly an identical expression pattern to SPRY2 (data not shown) and
similar responsiveness to FGFs (Liu et al., 2003).
As an alternative to SPRY genes we also looked at expression of
another antagonist of FGF signaling: PYST1. PYST1 dephosphorylates
the activated threonine and tyrosine residues on ERK2 (Camps et al.,
1998), thereby also dampening the FGF signalling cascade (Eblaghie et
al., 2003). PYST1 is expressed in similar areas to SPRY2 in the
frontonasal mass and maxillary prominence (Figs. 2G–J). Similar to
SPRY2, PYST1 expression was largely ablated in the frontonasal mass
at both time points in cranially treated embryos (Fig. 2H; Table S2).
The caudal beads caused a local decrease in PYST1 expression mainly
restricted to the globular process at both time points (Fig. 2J; Table S2).
Overall, there were surprising long-distance effects on expression of
SPRY2 and PYST1 from cranial beads whereas beads in the globular
process did not exert their effects in a cranial direction.
The decrease in transcripts for three antagonists of FGF signaling,
SPRY2, SPRY4 and PYST1 could cause a disregulation of the down-
stream signalling cascade and a net increase in FGF signalling. To
determine whether or not this was true we looked at the amount of
phosphorylated ERK in the frontonasal mass with immunohistochem-
istry. Embryos with cranial beads had decreased staining along the
lateral edge of the frontonasal mass (n=4/4, Fig. S1B), comparedwith a
localized decrease surrounding the caudal bead position (n=4/4, Fig.
S1C). The effects on SPRY2, PYST1 and phospho-ERK support the
conclusion that there is a net decrease in the level of FGF signaling
caused by SU5402 implants, which results in cleft lip.
To determine whether transcription factors required for facial
morphogenesis were affected by SU5402 we look at expression of
MSX1 and MSX2. Both genes are downstream of FGF (Kettunen and
Thesleff, 1998; Mina et al., 2002) and BMP signaling (Ashique et al.,
2002a; Mina et al., 2002). FurthermoreMSX2 is more highly expressed
in the globular process while MSX1 is found in the entire lateral edge
of the frontonasal mass. In cranially-treated embryos there was
decreased expression ofMSX1 along the lateral edge of the frontonasal
mass including the globular process (6 h, n=4/4; Figs. 3A, B; Table S2)
Fig. 3.MSX1 andMSX2 expression are reduced in response to SU5402. Wholemount in situ hybridization in embryos treated with DMSO or SU5402-soaked beads (10 mg/ml). (A, D,
G, J) Expression domains are unaffected in controls.MSX1 andMSX2 expression is rapidly downregulated in cranial implants (B, H) and remains low 16 h later (C, I). (E, F, K, L) Caudal
bead treatment greatly reduced expression near the bead. Scale bar=500 μm. Key: fnm, frontonasal mass; gp, globular process; lnp, lateral nasal process; mdp, mandibular
prominence; mxp, maxillary prominence.
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Caudal bead implants had little effect on expression at both
timepoints (16 h: n=5/5; Figs. 3D–F).
MSX2 was greatly reduced following cranial SU5402 treatment
(n=5/5 for both time points, Figs. 3H, I). Globular process beads had an
even greater effect, either completely eliminating or signiﬁcantly
reducing expression (6 h, n=6/7, Fig. 3K; 16 h, n=6/6, Fig. 3L). This is
consistent with the fact that beads were placed directly into the area
of highest gene expression. The decrease in expression of FGF targets
further illustrate that FGF signalling is reduced and not essential for lip
fusion in the globular process.
FGF signaling in the cranial frontonasal mass is required to maintain cell
proliferation and cell survival
We hypothesized that the skeletal phenotypes were produced by
changes in cell proliferation and apoptosis and that these cellular
dynamics would vary in the two different bead positions. Several
studies have reported that the lateral edge of the frontonasal mass has
higher proliferation compared to the centre (MacDonald et al., 2004;
McGonnell et al., 1998; Wu et al., 2006, 2004). However, no study had
previously compared proliferation in the globular process to cranial
regions of the lateral frontonasal mass.On qualitative analysis of DMSO control or normal embryos, we
noted a striking absence of proliferating cells in the globular process
mesenchyme (Figs. 4A–F and data not shown, n=21/21). Other
observations were that immediately adjacent to the globular process
there were paired areas of high proliferation and in between these
regions in the centre of the frontonasal mass there was low
proliferation. In addition, themaxillarymesenchyme directly opposite
from the globular process had lower proliferation (n=17/17). These
patterns of proliferation were consistent in treated and untreated
sides of the face (Figs. 4C–F, H) as well as in DMSO controls (Figs. 4A,
B). Quantitative analysis of proliferation along the edge of the
frontonasal mass supported these observations (caudal third had
signiﬁcantly lower proliferation than the cranial third, pb0.05; Fig.
4G). This suggests that instead of acting as the leading edge, the
globular process is pushed or displaced towards the maxillary
prominence by the proliferation of more cranial mesenchyme.
In treated embryos, those with cranial beads had signiﬁcantly
decreased proliferation in the cranial two-thirds of the frontonasal
mass compared to the same region in DMSO controls (pb0.05; Figs.
4E, G). The overall cell density was similar in treated and control
embryos. The caudally-implanted SU5402 did not alter proliferation in
the caudal region even though the beads were directly in contact with
these cells (Figs. 4B, H). One explanation is that these cells are not
Fig. 4. Cell proliferation is selectively reduced in cranially treated embryos. Immunoﬂuorescence detection of BrdU antibody in frontal sections. Specimens were pulse-labeled for 2 h
with BrdU and ﬁxed 12 h after bead implantation with 10 mg/ml SU5402 or DMSO. Proliferating cells are green and nuclei are blue. Black arrowheads show low proliferation and
white arrows show high proliferation in all sections. Two sections from each specimen, shallow in the left panel and deeper in the right panel are represented in panels A–F. (A, B)
Control specimen showing normal patterns of proliferation. Lower proliferation is seen in the globular process and cranial maxillary prominence (dashed lines in panel A) as well as in
the centre caudal edge of the frontonasal mass. A band of proliferating cells is seen immediatelymedial to the low proliferation zone of the globular process (white arrows in B). Areas
counted are indicated with white grid in A. (C, D) No qualitative decrease in proliferation is seen. Areas of high proliferation (white arrows) are still present even though the bead is
located very close by. (E, F) Decreased proliferation caused by SU5402 (white arrowhead in (panel E). (G) Relative rate of proliferation in the regions indicated in panel A. Asterisk over
white bars show caudal third of the frontonasal mass has signiﬁcantly lower proliferation than the middle or cranial third. Asterisks on dark blue bars show signiﬁcantly lower
proliferation in cranially-treated embryos compared to the other treatments for a given region. (H) A different caudally-implanted specimen than in panel C, panel D showing caudal
proliferation is not reduced although the bead is right next to this region (white arrows). Bead is not in this section but position in adjacent section is noted with arrow. Scale
bar=500 μm; Key: b, bead; fnm, frontonasal mass; lnp, lateral nasal prominence; mxp, maxillary prominence.
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changes in the BrdU data could explain why globular process was
unaffected by SU5402 beads. In addition these data support the novel
idea that there is an FGF-dependent growth centre located near the
cranial-end of the nasal slit.FGF is known as a cell survival factor and targeted deletion of FGF8
in the face results in increased apoptosis (Trumpp et al., 1999). There is
normally no apoptosis along the lateral edge of the frontonasal mass
(McGonnell et al., 1998), except for low levels within the globular
process (Ashique et al., 2002a). With Nile blue staining, we observed
Fig. 5. Cell death is increased with SU5402. Embryos treated with 10 mg/ml SU5402 soaked beads. (A, B, E, F) Nile Blue staining. (C,D,G,H) TUNEL staining. White arrowheads indicate
apoptotic cells. (A) The cranial bead increased cell death along the edge of the nasal pit into the globular process. (B) Increased cell death near the caudal bead. Normal areas of cell
death are present in the groove between the lateral nasal andmaxillary prominence. (C, C′) Mesenchymal cell death is induced by the cranial bead but only background levels are seen
in caudal bead treatment (arrowheads in panel D′). (E) More extensive cell death extending to the telencephalon (upper arrowhead) is induced by the cranial bead. (F) Very localized
apoptosis surrounding the caudal bead (arrowheads). (G, G′) Persistent mesenchymal apoptosis is observed after cranial bead treatment. (H, H′) No detectable signal in the lateral
mesenchyme of the frontonasal mass. Scale bars: A=0.5 mm, applies to panels B, E, F; C=100 μm and applies to panels D, G, H; C′=100 μm and applies to panels D′, G′, H′. Key: fnm,
frontonasal mass; lnp, lateral nasal prominence; mxp, maxillary prominence; np, nasal pit.
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the effects of SU5402 are unilateral. Similar to the long distance effects
on gene expression, cranial beads increased cell death from the cranial
margin of the nasal slit down to the globular process (3 h: n=5/7, not
shown; 6 h, n=6/6, Fig. 5A; 9 h, n=3/4 Fig. 5E). Elevated apoptosis in
the mesenchyme was conﬁrmed in sections (Table S3; Figs. 5C, C′). In
contrast, the caudal bead position slightly enlarged the normal area of
cell death found in the globular process of the frontonasal mass (3 h:
n=6/7, not shown; 6 h: n=5/5, Fig. 5B; 9 h n=4/4, Fig. 5F). We found
that mesenchymal apoptosis had returned to normal levels 16 h after
caudal treatment (Figs. 5H, H′). There was no change in apoptosis in
any of the DMSO treated embryos demonstrating that the surgery
itself did not stimulate cell death (data not shown).
The nasal slit provides necessary FGF signals for frontonasal mass
morphogenesis
Through inserting SU5402 beads into the mesenchyme we have
shown that FGF signals from themesenchyme are required to promotecell survival and cell proliferation. However, the close proximity of the
beads to the nasal slit may have meant that we also interfered with
signals from this tissue. To determine whether FGF signalling within
the nasal slit was affected, we looked at expression of DLX5 a
transcription factor localized to this epithelium (Figs. S2A, D). Cranial
SU5402 decreased expression of DLX5 (n=6/6; Figs. S2A–C; Table S2)
providing the ﬁrst evidence that SU5402 is affecting the adjacent
epithelium.
In order to seewhether the nasal slit epithelium could be providing
FGF to the mesenchyme we did two types of experiments. The ﬁrst
was an extirpation experiment where as much of the olfactory
epithelium as could be removed was stripped from the nasal slit. We
then looked for changes in expression of PYST1. In sections of embryos
we found that the olfactory epithelium was partially removed with
this procedure (n=18/18, 0 and 6 h; Figs. S2E, F) and lead to a unilateral
decrease in PYST1 (n=5/8, Figs. S2G, H). These data suggest that in
addition to blocking mesenchymal FGF signalling with SU5402 we
may have also reduced FGF signalling originating in the nasal slit
epithelium.
Fig. 6. Effects of foil barriers inserted into the frontonasal mass. (A, B) embryos ﬁxed 16 h after foil barrier implantation demonstrate that the position of the foil is just medial to the
SPRY2 expression domain, leaving a smallmargin ofmesenchymebetween the foil and the nasal slit. In both embryos there is increased expression on the treated side of the face, on the
frontonasal mass and lateral nasal side of the nasal slit. The embryo in B had the foil removed before photography. (C, E) sagittal and ventral views showing the defect in the
premaxillary bone. This embryo also has a reduce nasal bone on the treated side (C). (D, F) Sagittal and ventral views of a different embryo with similar defects. The nasal bone is of
normal size in this embryo. Scale bars=500 μm for panels A, B and 2 mm for panels C–F. Key: mppmx, maxillary process of premaxilla; nb, nasal bone; mxb, maxillary bone; pmx,
premaxilla.
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mass, medial to the SPRY2 expression domain at stage 25. We have
already shown that SPRY2 is sensitive to levels of FGF signaling and
therefore selected this gene to obtain a readout of whether FGF levels
had changed in the frontonasal mass as a result of putting in the foil.
We also targeted the foil barrier to the cranial half of the nasal slit, an
area determined with our bead experiments to be dependent on FGFs
and medial to the SPRY2 expression domain. We wanted to determine
whether FGFs would accumulate in the facial mesenchyme adjacent to
the nasal slit with a barrier in place. We found that SPRY2 was
increased in the lateral edge of the frontonasal mass in a majority of
embryos (n=9/11, Figs. 6A, B). This corroborates with the previously
described directional effects of cranial SU5402 beads. An unexpected
result was the upregulation in the lateral nasal prominence (n=7/11,
Figs. 6A, B). The data suggests that the foil barrier resulted in the
ampliﬁcation of FGF signaling and it was high enough to trigger the
upregulation of SPRY2 in this region.
We looked at the effects on the skeleton to seewhether the foil had
interfered with frontonasal mass morphogenesis. Externally the foil
implanted embryos did not have clefts in the side of the beak as with
the SU5402 embryos, however internally, there was an obvious
shortening of the maxillary process of the premaxillary bone on the
treated side in all but one of the embryos (n=12/13, Figs. 6C–F). This is
almost identical to the SU5402 phenotype and suggests that the foil is
not interfering with fusion but nonetheless has similar effects on
skeletogenesis to the SU5402 beads. The reasons for the skeletal
phenotype are unclear but may relate to the increase in SPRY2
expression, perhaps resulting in a dampening of FGF signaling. Insummary, the foil barrier experiments increased SPRY2 expression but
we needed further evidence to say whether FGF signaling was
decreased or increased. We therefore performed the complementary,
gain-of-function experiment in which FGF2 beads were implanted
and compared the phenotypes.
Increased FGF signaling does not induce precocious fusion
We predicted that a local increase in FGF signaling, especially in
the cranial, FGF-dependent position would induce a burst of
proliferation and perhaps lead to abnormal or early contact between
the globular process and maxillary prominence or nasal cavity, such
early contact could lead to precocious fusion of the lip. However, we
found that embryos that were treated in the cranial region of the
frontonasal mass developed normally (n=19/22) and there was no
evidence of precocious fusion in serially sectioned embryos at any of
the timepoints examined (12 h, n=4; 56 h, n=8, Fig. 7I and data not
shown). In contrast, the caudally treated embryos had either partial
(Figs. 7B, E, F) or complete clefts (Fig. 7C, n=3/11). The early
morphology produced by caudal FGF2 was a more rounded globular
processes (n=19/33; compare Figs. 7A to B, C) an effect not seen with
Tris-soaked beads (n=17/18; Fig. 7A). In the material examined, we
did not detect ectopic contact between the frontonasal mass and the
nasal cavity, however it is possible that due to the complex nature of
the nasal passages some small areas of contact with the maxillary
prominences could have been present. The most obvious difference in
the FGF2 treated tissue was that the nasal cartilage was often
displaced to the left (n=9/11, Figs. 7E, F) possibly due to asymmetric
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thickness in either cranial or caudal FGF2 bead implants. To
determine whether these early effects on early morphology had
any consequences on skeletal development, we allowed a series of
embryos to develop until the beak had fully formed. We found that
the FGF2 soaked beads placed in the caudal bead position reduced
the outgrowth of the upper beak, making it slightly shorter than the
lower beak (n=7/13), and in a few cases resulting in minor cleftsbetween the premaxilla and palatine process of the maxillary bone
(affecting the roof of the mouth and not the side of the beak)
however these were much less severe than those reported for
SU5402 (n=7/13, Fig. 7G). Thus embryos had a different phenotype
from either those produced by SU5402 or foil-barriers.
To determine whether the shape changes in the FGF2-treated
embryos were due to an increase in proliferation, we looked at BrdU
incorporation. There were many more cells labeled in the treated
Fig. 8. Regions of FGF dependence and independence in the developing face. FGF
signaling (red) from upper frontonasal mass (mesenchymal and epithelial) promotes
proliferation and cell survival. Displacement of the globular process is caused by
expansion and relatively higher proliferation of the cranial frontonasal mass
mesenchyme (black arrows). FGF signaling is less important in the globular process
and cranial maxillary prominence. In these two regions BMP in the mesenchyme
positively regulates MSX1 and MSX2 expression and represses FGF8 and SHH in the
epithelium (Ashique et al., 2002a). Areas of high proliferation overlap all of the FGF-
dependent regions and also a small area in the caudal edge of the frontonasal mass that
is dependent on BMP signals.
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(Fig. 7I) and caudal bead positions (Figs. 7J–J ) The expansion of
mesenchyme at this early timepoint (12 h post bead implantation)
would undoubtedly the cause of the deviated nasal cartilage seen at
later timepoints (Figs. 7E, F) There was also a clear increase in the
central frontonasal mass (Figs. 7I–J′), an area that we have previously
deﬁned as having relatively low proliferation in the normal embryo
(Fig. 7H; MacDonald et al., 2004). Remarkably however, the beads
did not increase proliferation within the globular process, even
though the beads were placed in direct contact with this mesen-
chyme (Figs. 7J, J′, n=5/5). Moreover the FGF2 protein was able to
stimulate proliferation in the cranial frontonasal mass (n=5/5; Figs.
7I–K) an area we had shown to be FGF-dependent. The responses to
FGF2 are therefore similar to those obtained with SU5402 and
further highlight the independence of the globular process from FGF
signaling.Fig. 7. Effects of exogenous FGF2 onmorphogenesis, proliferation and gene expression. Embry
K,M, N) or SU5402-soaked beads (P, Q). (A, D) Normal morphology at 55 h showing narrow
embryo in B is less affected than in C. The embryo in C has a cleft (arrow) and looks similar to a
55 h post bead implantation, stained with Toluidine blue. (E, F) Two near adjacent sections fr
between the nasal and oral cavities (arrow). The prenasal cartilage is displaced towards left (
reduction of the palatine process of the maxillary bone and nasal process of the palatine bone
the zone of fusion and along the caudal edge (white arrowheads) and high proliferation in th
The globular process and caudal edge of the frontonasal mass of treated embryos have low pro
globular process epithelium compared to the untreated (left) side. (K–N) FGF2 beads activ
eliminated at early timepoints and recovers along the caudal edge by 16 h (continued loss of e
N. (S–U) SU5402 had no effect even though the bead was directly in contact with expressing e
K–U. Key: fnm, frontonasal mass; gp, globular process; md, mandibular prominence; mxp
palatine process of maxillary bone.The previous experiments with SU5402 had shown SPRY2 and
MSX2 to be targets of the FGF pathway. As expected, there was
signiﬁcant upregulation in embryos treated with cranial (Figs. 7L, M,
n=4/4 for MSX2 and 6/6 for SPRY2) or caudal beads (Figs. 7N,O n=5/5
for both genes) that extended many hundreds of microns away from
the bead. The negative feedback loopwhere the agonist FGF induces its
antagonist SPRY2 is similar to that reported by others (Chambers and
Mason, 2000). Therewas a striking correlation between the areas with
increased proliferation and increased gene expression with the
exception of the globular process. As described previously, prolifera-
tion in the globular process remained low even though FGF2 induced
expression of SPRY2 andMSX2. We therefore hypothesized that BMP4,
which is expressed in the globular process and is required for
proliferation in this region (Ashique et al., 2002a) was decreased in
response to FGF2.
BMP4 expression is largely complementary to that of FGF8, a
pattern that is repeated in themandibular andmaxillary prominences.
As a consequence of conditional deletions of Bmp4 there often is an
expansion of Fgf8 (Liu et al., 2005), therefore reciprocal regulation is
thought to be taking place. The prediction is that BMP4 should be
repressed by FGF2 and increased by SU5402. Indeed BMP4 expression
was completely lost at 6 h after FGF2 beads were implanted (n=4/4,
Fig. 7M). The downregulation was maintained in the nasal slit
(arrowhead, n=3/3, Fig. 7N) but not the caudal edge epithelium 16 h
after implantation. It is possible that the loss of BMP4 helps to keep
proliferation low in the globular process. We compared these FGF2
data to the effects of SU5402 and neither the caudal (Figs. 7P, Q; 6 h,
n=5/6; 16 h, n=6/6) nor cranial SU5402 beads (data not shown; 6 h,
n=5/5; 16 h, n=5/5) affected BMP4 expression. Therefore there is a
feedback loop such that FGF signaling is not required to maintain
BMP4 expression but instead FGFs may act to restrict BMP4 to speciﬁc
regions of facial ectoderm.
Discussion
Here we have shown novel roles for FGF signaling in the face
including the regulation of shape and volume in the facial promi-
nences. Furthermore, through our analysis of the response to the
cranial and caudal bead positions we localized the areas of greatest
FGF responsiveness to the cranial and lateral edge of the frontonasal
mass, whereas the globular process and cranial maxillary promi-
nences are not dependent on FGF signalling. Together these regions
are coordinated so that the physical association of the facial
prominences occurs at the correct time and place of development.
The nasal slit epithelium, which expresses both FGF8 and FGF10, is one
important source of FGF signals.
Loss of FGFR signaling gives rise to the skeletal deletions
The SU5402 experiments led to a net reduction of endogenous FGF,
even though there are decreased transcripts for intracellular inhibitors
of the FGF signal (SPRY2, 4, PYST1). These data are further supported
by the loss of Phospho-Erk staining and the decreased expression of 2os treated with either Tris buffer-soaked (A, D, H, L), FGF2-soaked (1mg/ml; B, C, E–G, I–
frontonasal mass. (B, C) An increase in size of the right frontonasal mass (arrow). The
duck embryo of an equivalent stage (Wu et al., 2006). (D–F) Frontal sections of embryos
om the embryo in panel B displaying a thinner fusion zone (arrow) and communication
arrowheads). (G) Palatal view of a caudally implanted FGF2 embryo at stage 37 showing
. (H–J) BrdU labeling 12 h after bead implantation, showing areas of low proliferation in
e centre of the frontonasal mass (black arrowheads). Beads indicated with white circles.
liferation similar to controls. Higher power views showno change in proliferation in the
ate target genes 16 h post bead implantation (arrowheads). (P–R) BMP4 expression is
xpression in nasal slit is indicated by arrows). Note swelling of globular process in panels
pithelia. Scale bars=1 mm for panels A–K, 200 μm for panels J′, J and 500 μm for panels
, maxillary prominence; npp, nasal process of palatine bone; ns, nasal septum; ppmx,
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consistent with a loss of FGF signaling and are similar to the results of
gene targeting of Fgf ligands in mice. The conditional knockouts
(Kawauchi et al., 2005; Macatee et al., 2003; Trumpp et al., 1999) and
hypomorphic alleles of Fgf8 (Abu-Issa et al., 2002; Frank et al., 2002)
have reduced maxillary and premaxillary bones, coincident with the
foreshortening of the upper face (Kawauchi et al., 2005; Macatee et al.,
2003). Although no cleft lips were observed in the various FGF
knockoutmice, the losses of distal facial bones are similar to the loss of
bones in cranially treated SU5402 treated embryos.
What is the interpretation of the foil barrier data then, in which
SPRY2 expression is increased and yet a phenotype almost identical
to SU5402 is produced? There are two possibilities to consider. One is
that the increased SPRY2 lead to a decrease in the level of FGF
signaling. Although the foil has allowed the FGF protein to build up in
the lateral edge of the frontonasal mass, the concomitant upregulation
of SPRY2 leads to a reduction in FGF signalling. Further evidence in
support of this idea is that the foil experiment gives different results to
those obtained with FGF2 bead implants.
Another possibility is that the tissues medial to the foil are
prevented from receiving an FGF signal and it is these regions that give
rise to the lateral process of the premaxilla. There are no precise maps
of the frontonasal mass in which speciﬁc skeletal elements are
mapped onto a stage 24–28 frontonasal mass, however there are data
showing that the lateral edge and globular process of the frontonasal
mass contribute to the sides of the upper beak (Hu et al., 2003). The
centre of the beak is derived from cells in themidline and at the caudal
edge of the frontonasal mass. Based our knowledge of the upper beak
skeleton in relation to the overlying soft tissues, we can deduce that
the centre of the beak is derived from cells in the midline and at the
caudal edge of the frontonasal mass whereas the maxillary process of
premaxilla originates in the lateral edge of the frontonasal mass. We
correlate the region in which SPRY2 was upregulated in the foil
implants with the mesenchyme that gives rise to the maxillary and
palatine process of the premaxilla. DiI labeling of the frontonasal mass
showed that cells labeled in the area closest to the foil position mainly
expand vertically and not as much laterally (McGonnell et al., 1998).
Therefore we should not have interfered with the normal cellular
movements at that stage. Work from others has shown that, retroviral
over-expression of SPRY2 in the face lead to a cleft beak with major
loss of skeletal elements (Goodnough et al., 2007). Thus we conclude
that SPRY2 is one gene expressed in the right place and right time to
affect skeletogenesis in foil implanted embryos but we cannot rule out
that additional genes mediate this process.
In summary, the foil barriers can phenocopy some of the effects of
cranial SU5402 beads and it is primarily on this basis, that we
conclude foils are disrupting FGF signaling, possibly via upregulation
of the antagonist, SPRY2.
Hierarchy of signaling in facial prominences shows BMPs to be acting
upstream of FGFs
The cranial and lateral edges of the frontonasal mass, caudal
maxillary prominence have high SPRY expression and are ﬂanked by
zones that are largely controlled by BMP signals. BMP-dependence has
been demonstrated in bothmouse and chicken embryos. For example,
conditional deletion of Bmp4 in themandibular epithelium speciﬁcally
disturbed distal development (Liu et al., 2005), the area spared in the
Fgf8 conditional knockouts (Trumpp et al., 1999). Furthermore, our
previous studies on chicken showed that endogenous BMPs are
required for development of the globular process and anterior
maxillary prominence (Ashique et al., 2002a). The primary roles of
endogenous Bmps in the globular process are to 1) regulate prolifera-
tion and 2) to regulate thickness of the epithelia which must be
thinned and removed for a mesenchymal connection to form (Ashique
et al., 2002a). This latter conclusion is based on the thickening ofepithelium and upregulation of FGF8 following treatment of the
globular processwith Noggin. In contrast, in the present study, FGFs do
not appear to be involved in regulating epithelial survival since
exogenous FGFs do not result in detectable thickening of the
epithelium in tissue sections.
Previous data with Noggin beads (Ashique et al., 2002a) has
shown that BMPs are upstream of Fgf genes and that normally the
role of BMPs is to repress Fgf8 expression in the globular process. In
the mouse model, conditional deletion of Bmp4 in the mandibular
epithelium expands Fgf8 expression towards the midline, an area
that normally expresses Bmp4 (Liu et al., 2005). Therefore not only
are BMPs upstream of FGFs, the chicken and mouse data agree that
the role of BMPs is to repress the expression domain of FGF8. We
extend these results here and show that blocking FGF signalling had
no effect on BMP4 expression, conﬁrming in a complementary
experiment that FGFs are not upstream of BMPs. Once again, these
results on chicken are similar to those obtained in the Fgf8
conditional knockout mice, where there is no effect on Bmp4
expression in the mandibular prominence (Trumpp et al., 1999).
It is also interesting that the same transcription factors lie
downstream of BMP and FGF signaling, MSX1, MSX2. We have
shown that MSX2 transcripts in the globular process are dependent
on BMP signaling (Ashique et al., 2002a) and FGF signaling. However
during normal morphogenesis FGFs are not active in the globular
process and BMPs take over the role of maintainingMSX2 expression.
MSX2 is associated with cleft lip in humans (van den Boogaard et al.,
2000) and now we have shown that disruptions in either the FGF or
BMP signaling pathways can affect MSX2 and give rise to a cleft. These
data demonstrate that there is crosstalk between FGF and BMPs and
their downstream effector molecules in the globular process.
The chicken embryo data provide experimental validation and a
mechanism for how FGF signaling is used during human lip fusion
The data presented here showed that mainly it is decreased FGFR
signaling in the lateral edge of the frontonasal mass that induced a
cleft lip. Those clefts induced by FGF2 are minor and for the most part
embryos recover and develop normally from this insult. In the case
where there is too little FGF signaling, contact between adjacent
prominences is not made at the critical time and this is the principal
reason for the failure of fusion. Such studies are relevant to human
clefting because promoting better growth in the early phases of facial
development would facilitate fusion. Further explorations into the
precise timing, size and shape analysis of the facial prominences
during upper lip fusion (Diewert andWang, 1992; Diewert et al., 1993;
Wang et al., 1995) will provide valuable insights into spectrum of
severity within human orofacial clefting.
The association between FGF signaling and orofacial clefting in
humans has recently been solidiﬁed due to identiﬁcation of loss-of-
functionmutations in FGFR1 in Kallmann syndrome,whichhas cleft lip
as part of the phenotype (Dode et al., 2007; Dode et al., 2003) and the
ﬁnding of missense mutations in various FGF pathway genes in
populations with isolated clefts (Riley et al., 2007a). Kallmann
syndrome is particularly interesting to us because patients present
with anosmia as well as cleft lip. Our data from extirpation
experiments and foil barriers showing that nasal slit epithelium
provides at least some of the FGF present in the frontonasal mass
provides a mechanism for how nose and facial defects could arise
together. It is very intriguing that the Twirler mouse also has a
combination of cleft lip and olfactory nerve deﬁcits (Gong, 2001; Gong
et al., 2000). The gene mutated in Twirler mice has not been identiﬁed
but genes in the FGF pathway that occur in the affected locus should be
examined carefully.
The FGF pathway genes with variant alleles in populations with
isolated CL/P (cleft lip with or without cleft palate) include FGF8,
FGFR1, FGFR2, and FGFR3 (Riley et al., 2007a). In addition, genome-
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are linked to clefting. FGFR1 is contained within this region (Riley et
al., 2007b). Moreover, several of the genes found to be regulated by
FGFs in our study such as MSX1, MSX2 and SPRY2 have also been
linked to non-syndromic human CL/P (Jezewski et al., 2003; Suzuki et
al., 2004; Vieira et al., 2005). Our work provides the ﬁrst experimental
evidence that loss of FGF signaling from the cranial region of the
frontonasal mass disturbs outgrowth. Our data from FGF2 bead
implants, also suggest that gain-of-function mutations in FGF
signaling could lead to craniofacial abnormalities.
Growth factor signalling and morphogenesis of species-speciﬁc form
The morphogenesis of species speciﬁc form is dependent on
coordination of growth factor signalling in different regions of the face
as proposed by Chuong and colleagues (Wu et al., 2006). In their
model the chicken beak has higher proliferation in the corners and
this is followed by convergence of the two lateral domains into one
area of high proliferation in the centre of the beak (Wu et al., 2006,
2004). At an equivalent morphological stage, these authors found that
the broad-billed duck does not lose the higher proliferation at the
corners, thereby it has a wider frontonasal mass. It is interesting that
we have converted the morphology of the chicken frontonasal mass to
be more duck-like with FGF2 beads placed in the globular process and
this morphology change is due to increased proliferation. Since the
effects from protein-soaked beads are unilateral and transitory,
increases in beak width were not seen. Nonetheless, we agree with
the model proposed by Wu and colleagues that higher lateral
proliferation leads to a broader morphology (Wu et al., 2006).
FGF-dependent regions are the main growth centres of the face
The placement of SU5402 beads showed a high requirement for FGF
signalling in the lateral frontonasal mass corresponding to areas of
high BrdU labeling but not medially where low BrdU labeling is found.
These lateral regions are also very responsive to exogenous FGFs. We
propose that most of the growth in the frontonasal mass occurs in the
lateral edges of the frontonasal mass under the inﬂuence of the FGF-
rich nasal slit (Fig. 8). This results in caudal or vertical displacement of
the globular process and edge of the frontonasal mass.
We have uncovered two things in this study: the signalingmolecules
that contribute, and a biomechanical explanation for the clefting phe-
notype. The cleft embryos in this study had a reduced volumewithin the
cranial frontonasal mass, which prevented the vertical displacement of
the globular process towards the anterior maxillary prominence.
The displaced regions are mainly dependent on other growth
factors and less so on FGFs. For example, near the edge of the
frontonasal mass there is high expression of BMP7 and BMP4 (Ashique
et al., 2002a,b). Furthermore, when BMP signaling is blocked with
Noggin protein there is a reduction in the already low rate of pro-
liferation and clefts are induced (Ashique et al., 2002a). Thus ourmodel
of facial morphogenesis is comprised of FGF signalling mainly occurr-
ing in the lateral and cranial edges of the frontonasalmass,whereas the
centre and globular processes are BMP independent (Fig. 8).
We proposed a modiﬁcation of the beak morphogenesis model to
say that FGF is also a major signal controlling midfacial growth. We
have also reﬁned the model to locate these different FGF and BMP-
dependent domains in relation to areas of high and low proliferation
(Fig. 8). Such experimentation using the highly varied bird beak and
other animal models with divergent facial morphologies will reveal
more about the universality of these mechanisms.
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